甲磺酸伊马替尼联合干扰素α-1b治疗慢性粒细胞白血病的临床效果分析

Clinical Effect Analysis of Imatinib Mesylate Combined with Interferon α-1b in the Treatment of Chronic Myeloid Leukemia

目的分析甲磺酸伊马替尼联合干扰素α-1b治疗慢性粒细胞白血病的临床疗效。方法选择2019年1月2020年1月本溪市中心医院收治的慢性粒细胞白血病患者60例,依据治疗方案的不同分为对照组和观察组各30例,对照组接受甲磺酸伊马替尼单药治疗,观察组采用甲磺酸伊马替尼联合干扰素α-lb治疗,分析两组的治疗效果。结果观察组完全血液学缓解率、完全分子学缓解率和完全细胞遗传学缓解率均高干对照组,差异均有统计学意义(P<0.05)。观察组不良反应总发生率低干对照组,差异有统计学意义(P<0.05)。治疗后观察组乳酸脱氢酶、α-经基丁酸脱氢酶和碱性磷酸酶水平均低干对照组,差异均有统计学意义(P<0.05)。治疗后观察组生活质量评分高于对照组,差异有统计学意义(P<0.05)。结论甲磺酸伊马替尼联合干扰素α-lb治疗慢性粒细胞白血病的疗效优干甲磺酸伊马替尼单独用药方案,而且能够进一步改善患者的生活质量,值得推荐。

Objective To investigate the effects of imatinib mesylate combined with recombinant human interferon α-1b in the treatment of patients with chronic myeloid leukemia(CML).Methods A total of 60 patients with CML admitted to Benxi Central Hospital from January 2019 to January 2020 were selected,and divided into the control group and the observation group with 30 cases in each group according to the different treatment options.The control group was treated with imatinib mesylate monotherapy,and the observation group was treated with imatinib mesylate combined with interferon α-1b.The therapeutic effects of the two groups were analyzed.Results The complete hematological remission rate,complete molecular remission rate and complete cytogenetic remission rate in the observation group were significantly higher than those of the control group(P<0.05).The total incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05).After treatment,the levels of lactate dehydrogenase,a-hydroxybutyrate dehydrogenase and alkaline phosphatase in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the quality of life score of the observation group was significantly higher than that of the control group(P<0.05).Conclusion Imatinib mesylate combined with interferonα-1b is more effective than imatinib mesylate alone in the treatment of CML,and it can further improve the quality of life of patients,which is worthy of recommendation.